Bicocca Open Archive

Logo unimib boa
INVERNIZZI, PIETRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.469
AS - Asia 18.921
EU - Europa 15.805
SA - Sud America 2.890
AF - Africa 492
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 16
Totale 67.620
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.764
SG - Singapore 6.842
IT - Italia 3.799
CN - Cina 3.501
SE - Svezia 3.353
HK - Hong Kong 2.860
VN - Vietnam 2.715
RU - Federazione Russa 2.232
BR - Brasile 2.174
DE - Germania 1.724
CA - Canada 1.430
IE - Irlanda 1.288
GB - Regno Unito 763
FR - Francia 612
BD - Bangladesh 548
IN - India 487
AT - Austria 354
UA - Ucraina 354
FI - Finlandia 336
AR - Argentina 302
ID - Indonesia 281
TR - Turchia 254
KR - Corea 245
IQ - Iraq 210
NL - Olanda 210
CH - Svizzera 155
ZA - Sudafrica 149
JP - Giappone 146
ES - Italia 145
MX - Messico 139
PK - Pakistan 130
PL - Polonia 117
PH - Filippine 110
SA - Arabia Saudita 103
EC - Ecuador 94
DK - Danimarca 92
CO - Colombia 79
UZ - Uzbekistan 74
VE - Venezuela 68
MA - Marocco 67
MY - Malesia 64
BE - Belgio 46
DZ - Algeria 43
PY - Paraguay 43
CL - Cile 42
KE - Kenya 42
EG - Egitto 40
LT - Lituania 37
PE - Perù 36
JO - Giordania 35
JM - Giamaica 34
AE - Emirati Arabi Uniti 32
IL - Israele 30
TN - Tunisia 29
CZ - Repubblica Ceca 28
ET - Etiopia 28
TW - Taiwan 26
AZ - Azerbaigian 25
RO - Romania 25
NP - Nepal 22
UY - Uruguay 22
AU - Australia 21
BO - Bolivia 21
GR - Grecia 21
IR - Iran 21
PT - Portogallo 21
PS - Palestinian Territory 20
CR - Costa Rica 19
KZ - Kazakistan 18
LB - Libano 18
AL - Albania 17
TH - Thailandia 17
OM - Oman 15
PA - Panama 15
SN - Senegal 15
RS - Serbia 12
SY - Repubblica araba siriana 12
DO - Repubblica Dominicana 11
NG - Nigeria 11
SK - Slovacchia (Repubblica Slovacca) 11
TT - Trinidad e Tobago 11
BG - Bulgaria 10
HN - Honduras 10
HU - Ungheria 9
GT - Guatemala 8
MM - Myanmar 8
NI - Nicaragua 8
QA - Qatar 8
A2 - ???statistics.table.value.countryCode.A2??? 7
AO - Angola 7
KG - Kirghizistan 7
LY - Libia 7
NO - Norvegia 7
SC - Seychelles 7
EU - Europa 6
LA - Repubblica Popolare Democratica del Laos 6
MU - Mauritius 6
SR - Suriname 6
SV - El Salvador 6
BY - Bielorussia 5
Totale 67.500
Salva come PNG Salva come JPEG
Città #
Singapore 4.038
Ann Arbor 3.833
Hong Kong 2.787
Ashburn 2.345
Stockholm 1.908
Fairfield 1.778
San Jose 1.766
Woodbridge 1.346
Dublin 1.235
Toronto 1.146
Chandler 1.145
Frankfurt am Main 1.082
Wilmington 1.036
Houston 1.015
Milan 940
New York 858
Chicago 814
Ho Chi Minh City 789
Seattle 782
Cambridge 623
Hanoi 613
Los Angeles 601
Santa Clara 581
Dallas 563
Dearborn 501
Beijing 470
Princeton 469
The Dalles 453
Hefei 450
Jacksonville 376
Council Bluffs 329
Lauterbourg 297
Vienna 275
Boardman 272
London 246
Lawrence 229
Buffalo 228
Seoul 226
Nanjing 218
Moscow 216
Shanghai 216
Altamura 213
São Paulo 209
Jakarta 200
Helsinki 198
Rome 198
San Diego 139
Zurich 132
Orem 121
Nuremberg 119
Munich 116
Tokyo 106
Guangzhou 98
Haiphong 96
Da Nang 93
Rio de Janeiro 85
Dong Ket 78
Johannesburg 75
Florence 71
Montreal 71
Warsaw 70
Andover 68
Baghdad 68
Lachine 62
Salt Lake City 62
Monza 61
Tashkent 61
Biên Hòa 60
Hangzhou 60
Brooklyn 58
Atlanta 55
Nanchang 55
Turin 55
Changsha 54
Chennai 54
Naples 54
Columbus 53
Phoenix 52
Washington 50
Amsterdam 49
Dhaka 49
Bari 48
Denver 48
Ottawa 47
Bologna 46
Istanbul 45
Belo Horizonte 44
Boston 44
Can Tho 44
Hải Dương 44
Pune 44
Mumbai 43
Brussels 42
Shenyang 42
Tampa 42
Elk Grove Village 41
Hebei 41
Tianjin 41
Jinan 40
Lappeenranta 38
Totale 43.547
Salva come PNG Salva come JPEG
Nome #
Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial 1.949
Improvements and future perspective in diagnostic tools for neuroendocrine neoplasms 728
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 588
Validation of the Italian version of fisk fatigue severity score (FFSS) and PBC-40 514
Impact of multidisciplinary team approach to liver tumors in a tertiary center: 5-years experience 491
Dexamethasone Conjugation to Biodegradable Avidin-Nucleic-Acid-Nano-Assemblies Promotes Selective Liver Targeting and Improves Therapeutic Efficacy in an Autoimmune Hepatitis Murine Model 454
Exploring the landscape of steatotic liver disease in the general US population 433
A worldwide cross-ethnic study of quality of life in patients with PBC: Attitude or latitude? 432
Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison 408
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 394
A second update on mapping the human genetic architecture of COVID-19 364
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response 348
A short version of a HRQoL questionnaire for Italian and Japanese patients with Primary Biliary Cirrhosis 346
Mapping the human genetic architecture of COVID-19 345
Endocrinology and Metabolic Diseases (Including Diabetes) 342
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 340
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 338
Knockout of α-calcitonin gene-related peptide attenuates cholestatic liver injury by differentially regulating cellular senescence of hepatic stellate cells and cholangiocytes 338
Risk stratification in primary sclerosing cholangitis 334
Accuracy of Liver Stiffness Measurement in assessing liver fibrosis in naïve patients with Primary Biliary Cholangitis 334
Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms 331
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development 330
Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 Knockout Mice via Lethal-7 microRNA 329
Precision medicine in primary biliary cholangitis 328
Hepatic focal nodular hyperplasia after pediatric hematopoietic stem cell transplantation: The impact of hormonal replacement therapy and iron overload 323
FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study 318
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 318
Understanding short bowel syndrome: Current status and future perspectives 316
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 316
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 308
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 307
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma 306
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls 303
High rates of 30-day mortality in patients with cirrhosis and COVID-19 299
Dermatological Complications After Solid Organ Transplantation 298
DCLK1, a putative novel stem cell marker in human cholangiocarcinoma 296
Autoimmune liver diseases 294
A NOVEL MACHINE-LEARNING, COMMON VARIANTS-BASED APPROACH TO PREDICT PRIMARY BILIARY CHOLANGITIS 294
FRI-006-Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis 293
It's as if PBC didn’t exist: The illness experience of women affected by primary biliary cirrhosis 292
Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group 290
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis 287
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 287
New Therapeutic Targets in Autoimmune Cholangiopathies 284
Better end points needed in primary sclerosing cholangitis trials 282
Endoscopic Findings in Patients Infected With 2019 Novel Coronavirus in Lombardy, Italy 281
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies 280
The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective 280
THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis 279
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis 276
Intratumor Microbiome in Neuroendocrine Neoplasms: A New Partner of Tumor Microenvironment? A Pilot Study 275
The X-factor in primary biliary cirrhosis: Monosomy X and xenobiotics 273
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 273
The mode of dexamethasone decoration influences avidin-nucleic-acid-nano-assembly organ biodistribution and in vivo drug persistence 272
Clinical treatment of cholangiocarcinoma: an updated comprehensive review 270
miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation 268
Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland 268
Immune-mediated drug-induced liver injury: Immunogenetics and experimental models 266
Validation of the Japanese version of the Fisk Fatigue Severity Score (FFSS) in Japanese patients with primary biliary cirrhosis 265
Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis 263
Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis 262
Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth 261
The challenges of primary biliary cholangitis: What is new and what needs to be done 259
Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the " Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease 258
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis 258
Artificial Intelligence and liver: Opportunities and barriers 257
Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2−/− mice and human primary sclerosing cholangitis 257
Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 255
Y chromosome loss in male patients with primary biliary cirrhosis 252
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach 252
Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets 252
Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis 252
Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma 251
Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies 250
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 247
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. 246
Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells 245
The Seat of Life. What a Lesson from the Stigmatized Saints 245
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 243
Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth 242
Prognostic models in primary biliary cholangitis 241
Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion 240
AISF position paper on liver disease and pregnancy 240
Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis 238
Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature 237
Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma; its synthesis is reduced favoring cholangiocarcinoma growth 236
Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review 236
Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma 235
Reply to: “A spotlight on natural killer cells in primary biliary cholangitis” 234
Exploring the spectrum of incidental gastric polyps in autoimmune gastritis 233
Artificial intelligence for precision medicine in autoimmune liver disease 233
“I Miss My Liver.” Nonmedical Sources in the History of Hepatocentrism 233
FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 233
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 233
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe 229
Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers 229
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study 229
Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis 228
Deep learning helps discriminate between autoimmune hepatitis and primary biliary cholangitis 227
MicroRNAs in autoimmunity and inflammatory bowel disease: Crucial regulators in immune response 227
Totale 31.253
Salva come PNG Salva come JPEG
Categoria #
all - tutte 233.717
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 233.717
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021429 0 0 0 0 0 0 0 0 0 0 0 429
2021/20223.372 349 274 450 243 204 240 132 212 147 214 312 595
2022/20235.371 601 1.340 437 474 462 807 153 297 443 94 150 113
2023/20244.867 131 159 172 426 549 1.098 753 188 362 248 86 695
2024/202511.516 792 1.268 738 608 973 478 672 489 1.171 1.576 1.039 1.712
2025/202629.617 3.048 1.671 2.080 2.746 2.909 1.496 3.700 1.790 2.493 4.460 2.494 730
Totale 69.479